You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameZolpidem
Accession NumberDB00425  (APRD00095)
TypeSmall Molecule
GroupsApproved
DescriptionZolpidem is a prescription short-acting nonbenzodiazepine hypnotic that potentiates gamma-aminobutyric acid (GABA), an inhibitory neurotransmitter, by binding to benzodiazepine receptors which are located on the gamma-aminobutyric acid receptors. Zolpidem is used for the short-term treatment of insomnia. It works quickly (usually within 15 minutes) and has a short half-life (2-3 hours). It is classified as an imidazopyridine. As an anticonvulsant and muscle relaxant, the beneficial effects start to emerge at 10 and 20 times the dose required for sedation, respectively. For that reason, it has never been approved for either muscle relaxation or seizure prevention. Recently, zolpidem has been cited in various medical reports mainly in the United Kingdom as waking persistent vegetative state (PVS) patients, and dramatically improving the conditions of people with brain injuries. [Wikipedia]
Structure
Thumb
Synonyms
N,N,6-Trimethyl-2-(4-methylphenyl)imidazo(1,2-a)pyridine-3-acetamide
Zolpidem
Zolpidemum
External Identifiers
  • HSDB 7045
  • SL 800750
  • SL 800750-23N
  • UNII-7K383OQI23
  • UNII-WY6W63843K
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Ambientablet, film coated5 mg/1oralA S Medication Solutions Llc1993-04-01Not applicableUs
Ambientablet, film coated5 mg/1oralSanofi Aventis U.S. Llc1993-04-01Not applicableUs
Ambientablet, film coated10 mg/1oralRebel Distributors Corp.2009-06-30Not applicableUs
Ambientablet, film coated5 mg/1oralSTAT Rx USA LLC1993-04-01Not applicableUs
Ambientablet, film coated10 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2009-06-30Not applicableUs
Ambientablet, film coated10 mg/1oralbryant ranch prepack1993-04-01Not applicableUs
Ambientablet, film coated10 mg/1oralA S Medication Solutions Llc1993-04-01Not applicableUs
Ambientablet, film coated10 mg/1oralSanofi Aventis U.S. Llc1993-04-01Not applicableUs
Ambientablet, film coated10 mg/1oralSTAT Rx USA LLC1993-04-01Not applicableUs
Ambientablet, film coated5 mg/1oralA S Medication Solutions Llc1993-04-01Not applicableUs
Ambientablet, film coated10 mg/1oralA S Medication Solutions Llc1993-04-01Not applicableUs
Ambientablet, film coated5 mg/1oralRebel Distributors Corp.2009-06-30Not applicableUs
Ambien CRtablet, coated12.5 mg/1oralPd Rx Pharmaceuticals, Inc.2009-06-30Not applicableUs
Ambien CRtablet, coated12.5 mg/1oralA S Medication Solutions Llc2005-09-19Not applicableUs
Ambien CRtablet, coated12.5 mg/1oralRebel Distributors Corp.2009-06-30Not applicableUs
Ambien CRtablet, coated12.5 mg/1oralPhysicians Total Care, Inc.2009-11-24Not applicableUs
Ambien CRtablet, coated12.5 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2011-12-13Not applicableUs
Ambien CRtablet, coated12.5 mg/1oralbryant ranch prepack2009-06-30Not applicableUs
Ambien CRtablet, coated6.25 mg/1oralRebel Distributors Corp.2009-06-30Not applicableUs
Ambien CRtablet, coated6.25 mg/1oralSanofi Aventis U.S. Llc2005-09-19Not applicableUs
Ambien CRtablet, coated6.25 mg/1oralPhysicians Total Care, Inc.2005-10-07Not applicableUs
Ambien CRtablet, coated12.5 mg/1oralSTAT Rx USA LLC2009-06-30Not applicableUs
Ambien CRtablet6.25 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2011-11-10Not applicableUs
Ambien CRtablet, coated6.25 mg/1oralbryant ranch prepack2009-06-30Not applicableUs
Ambien CRtablet, coated12.5 mg/1oralSt Marys Medical Park Pharmacy2010-12-01Not applicableUs
Ambien CRtablet, coated12.5 mg/1oralSanofi Aventis U.S. Llc2005-09-19Not applicableUs
Edluartablet10 mg/1oralMeda Pharmaceuticals Inc.2009-07-24Not applicableUs
Edluartablet5 mg/1oralMeda Pharmaceuticals Inc.2009-07-24Not applicableUs
Intermezzotablet3.5 mg/1sublingualPurdue Pharma LP2012-04-05Not applicableUs
Intermezzotablet1.75 mg/1sublingualPurdue Pharma LP2012-04-05Not applicableUs
Ivadaltablet5 mgoralSanofi Aventis Canada IncNot applicableNot applicableCanada
Ivadaltablet10 mgoralSanofi Aventis Canada IncNot applicableNot applicableCanada
Sublinoxtablet (orally disintegrating)5 mgsublingualValeant Canada Lp Valeant Canada S.E.C.2013-01-28Not applicableCanada
Sublinoxtablet (orally disintegrating)10 mgsublingualValeant Canada Lp/valeant Canada s.e.c.2011-11-29Not applicableCanada
Zolpidem Tartratetablet, coated5 mg/1oralKAISER FOUNDATION HOSPITALS2008-10-01Not applicableUs
Zolpidem Tartratetablet, coated10 mg/1oralKAISER FOUNDATION HOSPITALS2008-10-01Not applicableUs
Zolpidem Tartratetablet, film coated, extended release6.25 mg/1oralWinthrop U.S, A Business Of Sanofi Aventis U.S. Llc2010-10-14Not applicableUs
Zolpidem Tartratetablet, film coated, extended release12.5 mg/1oralWinthrop U.S, A Business Of Sanofi Aventis U.S. Llc2010-12-06Not applicableUs
Zolpidem Tartratetablet, film coated, extended release12.5 mg/1oralAphena Pharma Solutions Tennessee, Llc2010-12-06Not applicableUs
Zolpidem Tartratetablet, film coated, extended release12.5 mg/1oralPhysicians Total Care, Inc.2010-12-16Not applicableUs
Zolpidem Tartrate ODTtablet (orally disintegrating)5 mgsublingualValeant Canada Lp Valeant Canada S.E.C.Not applicableNot applicableCanada
Zolpidem Tartrate ODTtablet (orally disintegrating)10 mgsublingualValeant Canada Lp Valeant Canada S.E.C.Not applicableNot applicableCanada
Zolpimistspray, metered5 mg/1oralMagna Pharmaceuticals, Inc.2016-03-21Not applicableUs
Zolpimistspray, metered5 mg/1oralECR Pharmaceuticals2010-12-01Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-zolpidem ODTtablet (orally disintegrating)10 mgsublingualApotex Inc2015-02-13Not applicableCanada
Apo-zolpidem ODTtablet (orally disintegrating)5 mgsublingualApotex Inc2015-02-13Not applicableCanada
Zolpidemtablet5 mg/1oralWest ward Pharmaceutical Corp2008-04-30Not applicableUs
Zolpidemtablet10 mg/1oralWest ward Pharmaceutical Corp2008-04-30Not applicableUs
Zolpidem Tartratetablet, film coated5 mg/1oralLake Erie Medical DBA Quality Care Products LLC2011-11-07Not applicableUs
Zolpidem Tartratetablet, film coated, extended release6.25 mg/1oralActavis Pharma, Inc.2010-10-13Not applicableUs
Zolpidem Tartratetablet, film coated, extended release12.5 mg/1oralA S Medication Solutions Llc2011-06-07Not applicableUs
Zolpidem Tartratetablet5 mg/1oralCardinal Health2011-01-28Not applicableUs
Zolpidem Tartratetablet, film coated10 mg/1oralDIRECT RX2014-01-01Not applicableUs
Zolpidem Tartratetablet, extended release6.25 mg/1oralbryant ranch prepack2011-10-31Not applicableUs
Zolpidem Tartratetablet, coated10 mg/1oralAmerican Health Packaging2014-01-07Not applicableUs
Zolpidem Tartratetablet10 mg/1oralAmerican Health Packaging2009-10-142015-12-29Us
Zolpidem Tartratetablet5 mg/1oralAidarex Pharmaceuticals LLC2007-09-05Not applicableUs
Zolpidem Tartratetablet10 mg/1oralTorrent Pharmaceuticals Limited2007-09-05Not applicableUs
Zolpidem Tartratetablet, film coated10 mg/1oralPd Rx Pharmaceuticals, Inc.2010-12-10Not applicableUs
Zolpidem Tartratetablet, film coated5 mg/1oralRoxane Laboratories, Inc2007-04-27Not applicableUs
Zolpidem Tartratetablet, film coated5 mg/1oralMylan Institutional Inc.2007-05-01Not applicableUs
Zolpidem Tartratetablet10 mg/1oralCardinal Health2009-11-02Not applicableUs
Zolpidem Tartratetablet, film coated5 mg/1oralApotex Corp.2007-04-23Not applicableUs
Zolpidem Tartratetablet5 mg/1oralProficient Rx LP2007-09-05Not applicableUs
Zolpidem Tartratetablet, film coated5 mg/1oralDispensing Solutions, Inc.2008-11-21Not applicableUs
Zolpidem Tartratetablet, film coated5 mg/1oralPreferred Pharmaceuticals, Inc.2015-02-23Not applicableUs
Zolpidem Tartratetablet, extended release6.25 mg/1oralSandoz Inc2011-10-31Not applicableUs
Zolpidem Tartratetablet10 mg/1oralWockhardt USA LLC.2007-05-15Not applicableUs
Zolpidem Tartratetablet, extended release12.5 mg/1oralLupin Pharmaceuticals, Inc.2014-04-07Not applicableUs
Zolpidem Tartratetablet5 mg/1oralPd Rx Pharmaceuticals, Inc.2007-09-05Not applicableUs
Zolpidem Tartratetablet, film coated10 mg/1oralBlenheim Pharmacal, Inc.2011-01-07Not applicableUs
Zolpidem Tartratetablet, film coated5 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2007-04-27Not applicableUs
Zolpidem Tartratetablet, film coated, extended release6.25 mg/1oralA S Medication Solutions Llc2010-10-13Not applicableUs
Zolpidem Tartratetablet, film coated, extended release6.25 mg/1oralWatson Laboratories, Inc.2013-03-25Not applicableUs
Zolpidem Tartratetablet, film coated, extended release6.25 mg/1oralPhysicians Total Care, Inc.2010-11-02Not applicableUs
Zolpidem Tartratetablet, film coated5 mg/1oralPd Rx Pharmaceuticals, Inc.2008-11-21Not applicableUs
Zolpidem Tartratetablet, extended release12.5 mg/1oralDIRECT RX2014-01-01Not applicableUs
Zolpidem Tartratetablet5 mg/1oralCarlsbad Technology, Inc.2007-04-23Not applicableUs
Zolpidem Tartratetablet, film coated10 mg/1oralbryant ranch prepack2008-11-21Not applicableUs
Zolpidem Tartratetablet10 mg/1oralRed Pharm Drug Inc.2008-11-21Not applicableUs
Zolpidem Tartratetablet, film coated5 mg/1oralMc Kesson Contract Packaging2011-10-20Not applicableUs
Zolpidem Tartratetablet1.75 mg/1sublingualGAVIS Pharmaceuticals, LLC2016-03-22Not applicableUs
Zolpidem Tartratetablet5 mg/1oralMajor Pharmaceuticals2009-11-02Not applicableUs
Zolpidem Tartratetablet, film coated10 mg/1oralNorth Star Rx Llc2007-05-04Not applicableUs
Zolpidem Tartratetablet, film coated5 mg/1oralAphena Pharma Solutions Tennessee, Llc2008-11-21Not applicableUs
Zolpidem Tartratetablet10 mg/1oralH.J. Harkins Company, Inc.2007-09-05Not applicableUs
Zolpidem Tartratetablet, film coated10 mg/1oralCardinal Health2007-04-23Not applicableUs
Zolpidem Tartratetablet10 mg/1oralBlenheim Pharmacal, Inc.2011-03-11Not applicableUs
Zolpidem Tartratetablet10 mg/1oralAidarex Pharmaceuticals LLC2007-09-05Not applicableUs
Zolpidem Tartratetablet5 mg/1oralA S Medication Solutions Llc2007-09-05Not applicableUs
Zolpidem Tartratetablet, film coated, extended release12.5 mg/1oralActavis Pharma, Inc.2011-06-07Not applicableUs
Zolpidem Tartratetablet, film coated, extended release6.25 mg/1oralA S Medication Solutions Llc2010-10-13Not applicableUs
Zolpidem Tartratetablet10 mg/1oralCardinal Health2011-01-28Not applicableUs
Zolpidem Tartratetablet, film coated5 mg/1oralDIRECT RX2014-01-01Not applicableUs
Zolpidem Tartratetablet, film coated5 mg/1oralbryant ranch prepack2008-11-21Not applicableUs
Zolpidem Tartratetablet, film coated, extended release12.5 mg/1oralAmerican Health Packaging2011-12-01Not applicableUs
Zolpidem Tartratetablet, extended release12.5 mg/1oralSandoz Inc2011-10-31Not applicableUs
Zolpidem Tartratetablet10 mg/1oralSTAT Rx USA LLC2007-09-05Not applicableUs
Zolpidem Tartratetablet, film coated10 mg/1oralPd Rx Pharmaceuticals, Inc.2008-11-21Not applicableUs
Zolpidem Tartratetablet, film coated10 mg/1oralRoxane Laboratories, Inc2007-04-27Not applicableUs
Zolpidem Tartratetablet, film coated10 mg/1oralMylan Institutional Inc.2007-05-01Not applicableUs
Zolpidem Tartratetablet5 mg/1oralCardinal Health2009-10-14Not applicableUs
Zolpidem Tartratetablet, film coated10 mg/1oralApotex Corp.2007-04-23Not applicableUs
Zolpidem Tartratetablet10 mg/1oralProficient Rx LP2007-09-05Not applicableUs
Zolpidem Tartratetablet, film coated10 mg/1oralDispensing Solutions, Inc.2008-11-21Not applicableUs
Zolpidem Tartratetablet, film coated5 mg/1oralPreferred Pharmaceuticals, Inc.2012-01-30Not applicableUs
Zolpidem Tartratetablet3.5 mg/1sublingualNovel Laboratories, Inc.2016-03-22Not applicableUs
Zolpidem Tartratetablet, film coated10 mg/1oralPd Rx Pharmaceuticals, Inc.2010-12-10Not applicableUs
Zolpidem Tartratetablet, extended release12.5 mg/1oralProficient Rx LP2011-10-31Not applicableUs
Zolpidem Tartratetablet10 mg/1oralTYA Pharmaceuticals2007-09-05Not applicableUs
Zolpidem Tartratetablet5 mg/1oralPreferred Pharmaceuticals, Inc.2007-09-05Not applicableUs
Zolpidem Tartratetablet, film coated10 mg/1oralREMEDYREPACK INC.2016-02-12Not applicableUs
Zolpidem Tartratetablet5 mg/1oralApotheca, Inc2007-07-25Not applicableUs
Zolpidem Tartratetablet, film coated10 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2007-04-27Not applicableUs
Zolpidem Tartratetablet, film coated10 mg/1oralUnit Dose Services2008-11-21Not applicableUs
Zolpidem Tartratetablet, film coated, extended release12.5 mg/1oralWatson Laboratories, Inc.2013-03-25Not applicableUs
Zolpidem Tartratetablet, film coated5 mg/1oralDr. Reddy's Laboratories Limited2007-04-23Not applicableUs
Zolpidem Tartratetablet, film coated5 mg/1oralA S Medication Solutions Llc2008-11-21Not applicableUs
Zolpidem Tartratetablet, film coated5 mg/1oralCardinal Health2007-04-232016-03-11Us
Zolpidem Tartratetablet10 mg/1oralCarlsbad Technology, Inc.2007-04-23Not applicableUs
Zolpidem Tartratetablet5 mg/1oralbryant ranch prepack2007-09-05Not applicableUs
Zolpidem Tartratetablet, film coated5 mg/1oralRed Pharm Drug Inc.2008-11-21Not applicableUs
Zolpidem Tartratetablet, film coated10 mg/1oralMc Kesson Contract Packaging2011-10-21Not applicableUs
Zolpidem Tartratetablet, film coated5 mg/1oralPreferred Pharmaceuticals Inc.2016-01-11Not applicableUs
Zolpidem Tartratetablet10 mg/1oralMajor Pharmaceuticals2009-11-02Not applicableUs
Zolpidem Tartratetablet5 mg/1oralRebel Distributors Corp.2007-09-05Not applicableUs
Zolpidem Tartratetablet10 mg/1oralMedsource Pharmaceuticals2007-09-05Not applicableUs
Zolpidem Tartratetablet, film coated10 mg/1oralBlenheim Pharmacal, Inc.2013-10-03Not applicableUs
Zolpidem Tartratetablet10 mg/1oralRx Change Co.2014-11-20Not applicableUs
Zolpidem Tartratetablet10 mg/1oralA S Medication Solutions Llc2007-09-05Not applicableUs
Zolpidem Tartratetablet, film coated5 mg/1oralMylan Pharmaceuticals Inc.2007-04-23Not applicableUs
Zolpidem Tartratetablet, film coated5 mg/1oralPhysicians Total Care, Inc.2007-10-09Not applicableUs
Zolpidem Tartratetablet, film coated5 mg/1oralCardinal Health2007-04-23Not applicableUs
Zolpidem Tartratetablet10 mg/1oralDIRECT RX2015-12-02Not applicableUs
Zolpidem Tartratetablet, film coated10 mg/1oralMc Kesson Packaging Services Business Unit Of Mc Kesson Corporation2011-06-01Not applicableUs
Zolpidem Tartratetablet, film coated, extended release6.25 mg/1oralAmerican Health Packaging2014-12-15Not applicableUs
Zolpidem Tartratetablet1.75 mg/1sublingualNovel Laboratories, Inc.2016-03-22Not applicableUs
Zolpidem Tartratetablet, coated5 mg/1oralSandoz Inc2007-04-23Not applicableUs
Zolpidem Tartratetablet5 mg/1oralSTAT Rx USA LLC2007-09-05Not applicableUs
Zolpidem Tartratetablet10 mg/1oralPd Rx Pharmaceuticals, Inc.2007-09-05Not applicableUs
Zolpidem Tartratetablet, film coated5 mg/1oralTeva Pharmaceuticals USA Inc2007-04-23Not applicableUs
Zolpidem Tartratetablet10 mg/1oralREMEDYREPACK INC.2013-05-22Not applicableUs
Zolpidem Tartratetablet10 mg/1oralCardinal Health2009-10-14Not applicableUs
Zolpidem Tartratetablet, film coated5 mg/1oralRanbaxy Pharmaceuticals Inc.2007-04-23Not applicableUs
Zolpidem Tartratetablet, film coated5 mg/1oralRed Pharm Drug, Inc.2007-05-04Not applicableUs
Zolpidem Tartratetablet, film coated10 mg/1oralPreferred Pharmaceuticals, Inc.2012-01-30Not applicableUs
Zolpidem Tartratetablet, film coated10 mg/1oralDr. Reddy's Laboratories Limited2007-04-23Not applicableUs
Zolpidem Tartratetablet, film coated5 mg/1oralWockhardt Limited2007-05-15Not applicableUs
Zolpidem Tartratetablet, film coated5 mg/1oralProficient Rx LP2008-11-21Not applicableUs
Zolpidem Tartratetablet, film coated5 mg/1oralAurobindo Pharma Limited2007-05-04Not applicableUs
Zolpidem Tartratetablet10 mg/1oralPreferred Pharmaceuticals, Inc.2007-09-05Not applicableUs
Zolpidem Tartratetablet10 mg/1oralApotheca, Inc2007-09-25Not applicableUs
Zolpidem Tartratetablet, film coated, extended release6.25 mg/1oralLake Erie Medical DBA Quality Care Products LLC2010-10-13Not applicableUs
Zolpidem Tartratetablet, film coated5 mg/1oralUnit Dose Services2008-11-21Not applicableUs
Zolpidem Tartratetablet, film coated5 mg/1oralQualitest Pharmaceuticals2008-11-21Not applicableUs
Zolpidem Tartratetablet, film coated10 mg/1oralA S Medication Solutions Llc2008-11-21Not applicableUs
Zolpidem Tartratetablet, film coated10 mg/1oralCardinal Health2007-04-232016-03-11Us
Zolpidem Tartratetablet, film coated10 mg/1oralREMEDYREPACK INC.2014-12-16Not applicableUs
Zolpidem Tartratetablet, extended release12.5 mg/1oralbryant ranch prepack2011-10-31Not applicableUs
Zolpidem Tartratetablet, coated5 mg/1oralAmerican Health Packaging2014-01-07Not applicableUs
Zolpidem Tartratetablet5 mg/1oralAmerican Health Packaging2009-10-142015-12-29Us
Zolpidem Tartratetablet, film coated10 mg/1oralProficient Rx LP2007-04-23Not applicableUs
Zolpidem Tartratetablet10 mg/1oralRebel Distributors Corp.2007-09-05Not applicableUs
Zolpidem Tartratetablet, film coated10 mg/1oralLake Erie Medical DBA Quality Care Products LLC2011-04-15Not applicableUs
Zolpidem Tartratetablet, film coated5 mg/1oralKAISER FOUNDATION HOSPITALS2015-09-15Not applicableUs
Zolpidem Tartratetablet, film coated10 mg/1oralPreferred Pharmaceuticals Inc.2016-01-20Not applicableUs
Zolpidem Tartratetablet, film coated5 mg/1oralBlenheim Pharmacal, Inc.2013-10-03Not applicableUs
Zolpidem Tartratetablet5 mg/1oralRx Change Co.2014-11-27Not applicableUs
Zolpidem Tartratetablet, film coated, extended release12.5 mg/1oralA S Medication Solutions Llc2011-06-07Not applicableUs
Zolpidem Tartratetablet, film coated10 mg/1oralMylan Pharmaceuticals Inc.2007-04-23Not applicableUs
Zolpidem Tartratetablet, film coated10 mg/1oralPhysicians Total Care, Inc.2009-07-01Not applicableUs
Zolpidem Tartratetablet, film coated10 mg/1oralCardinal Health2007-04-23Not applicableUs
Zolpidem Tartratetablet5 mg/1oralDIRECT RX2015-01-01Not applicableUs
Zolpidem Tartratetablet5 mg/1oralWockhardt USA LLC.2007-05-15Not applicableUs
Zolpidem Tartratetablet, extended release6.25 mg/1oralLupin Pharmaceuticals, Inc.2014-04-07Not applicableUs
Zolpidem Tartratetablet5 mg/1oralRed Pharm Drug Inc.2007-09-05Not applicableUs
Zolpidem Tartratetablet, film coated10 mg/1oralLife Line Home Care Services, Inc.2008-11-21Not applicableUs
Zolpidem Tartratetablet3.5 mg/1sublingualGAVIS Pharmaceuticals, LLC2016-03-22Not applicableUs
Zolpidem Tartratetablet, coated10 mg/1oralSandoz Inc2007-04-23Not applicableUs
Zolpidem Tartratetablet, film coated5 mg/1oralNorth Star Rx Llc2007-05-04Not applicableUs
Zolpidem Tartratetablet, film coated10 mg/1oralAphena Pharma Solutions Tennessee, Llc2008-11-21Not applicableUs
Zolpidem Tartratetablet, film coated10 mg/1oralTeva Pharmaceuticals USA Inc2007-04-23Not applicableUs
Zolpidem Tartratetablet, film coated10 mg/1oralREMEDYREPACK INC.2013-06-10Not applicableUs
Zolpidem Tartratetablet, film coated5 mg/1oralCardinal Health2007-04-23Not applicableUs
Zolpidem Tartratetablet5 mg/1oralSt Marys Medical Park Pharmacy2007-09-05Not applicableUs
Zolpidem Tartratetablet, film coated10 mg/1oralRanbaxy Pharmaceuticals Inc.2007-04-23Not applicableUs
Zolpidem Tartratetablet5 mg/1oralCardinal Health2009-11-02Not applicableUs
Zolpidem Tartratetablet, film coated10 mg/1oralWockhardt Limited2007-05-15Not applicableUs
Zolpidem Tartratetablet, film coated10 mg/1oralProficient Rx LP2008-11-21Not applicableUs
Zolpidem Tartratetablet, film coated10 mg/1oralAurobindo Pharma Limited2007-05-04Not applicableUs
Zolpidem Tartratetablet, film coated5 mg/1oralPreferred Pharmaceuticals, Inc.2015-02-23Not applicableUs
Zolpidem Tartratetablet5 mg/1oralTorrent Pharmaceuticals Limited2007-09-05Not applicableUs
Zolpidem Tartratetablet, film coated10 mg/1oralSTAT Rx USA LLC2008-11-21Not applicableUs
Zolpidem Tartratetablet, extended release12.5 mg/1oralUnit Dose Services2011-10-31Not applicableUs
Zolpidem Tartratetablet, film coated10 mg/1oralQualitest Pharmaceuticals2008-11-21Not applicableUs
Zolpidem Tartrate Extended Releasetablet, film coated, extended release12.5 mg/1oralSt Marys Medical Park Pharmacy2013-01-10Not applicableUs
Zolpidem Tartrate Extended-releasetablet, film coated, extended release6.25 mg/1oralPar Pharmaceutical, Inc.2011-04-14Not applicableUs
Zolpidem Tartrate Extended-releasetablet, film coated, extended release12.5 mg/1oralAvera Mc Kennan Hospital2015-06-29Not applicableUs
Zolpidem Tartrate Extended-releasetablet, film coated, extended release6.25 mg/1oralGolden State Medical Supply, Inc.2015-09-15Not applicableUs
Zolpidem Tartrate Extended-releasetablet, film coated, extended release12.5 mg/1oralPar Pharmaceutical, Inc.2011-12-06Not applicableUs
Zolpidem Tartrate Extended-releasetablet, film coated, extended release12.5 mg/1oralGolden State Medical Supply, Inc.2015-09-15Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AdormixSanofi Pasteur
Bikalmsanofi-aventis
Dormizolsanofi-aventis
HypnogenZentiva
IvedalWinthrop
NasenPolfarmex
NimadormSandoz
Nottemsanofi-aventis
Stilnoctsanofi-aventis
Stilnoxsanofi-aventis
Stilnox CRsanofi-aventis
ZolsanaKrka
ZoltisBiofarm
Brand mixtures
NameLabellerIngredients
Gabazolpidem-5Physician Therapeutics Llc
Sentrazolpidem PM-5Physician Therapeutics Llc
Salts
Name/CASStructureProperties
Zolpidem tartrate
ThumbNot applicableDBSALT001047
Categories
UNII7K383OQI23
CAS number82626-48-0
WeightAverage: 307.3895
Monoisotopic: 307.168462309
Chemical FormulaC19H21N3O
InChI KeyInChIKey=ZAFYATHCZYHLPB-UHFFFAOYSA-N
InChI
InChI=1S/C19H21N3O/c1-13-5-8-15(9-6-13)19-16(11-18(23)21(3)4)22-12-14(2)7-10-17(22)20-19/h5-10,12H,11H2,1-4H3
IUPAC Name
N,N-dimethyl-2-[6-methyl-2-(4-methylphenyl)imidazo[1,2-a]pyridin-3-yl]acetamide
SMILES
CN(C)C(=O)CC1=C(N=C2C=CC(C)=CN12)C1=CC=C(C)C=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenylimidazoles. These are polycyclic aromatic compounds containing a benzene ring linked to an imidazole ring through a CC or CN bond.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassAzoles
Sub ClassImidazoles
Direct ParentPhenylimidazoles
Alternative Parents
Substituents
  • 4-phenylimidazole
  • 5-phenylimidazole
  • Imidazopyridine
  • Methylpyridine
  • Toluene
  • Benzenoid
  • Pyridine
  • N-substituted imidazole
  • Monocyclic benzene moiety
  • Heteroaromatic compound
  • Tertiary carboxylic acid amide
  • Tertiary amine
  • Carboxamide group
  • Azacycle
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationFor the short-term treatment of insomnia.
PharmacodynamicsZolpidem is a sedative or hypnotic agent with a chemical structure unrelated to benzodiazepines, barbiturates, or other drugs with known hypnotic properties. It interacts with a GABA-BZ receptor complex and shares some of the pharmacological properties of the benzodiazepines. In contrast to the benzodiazepines, which non-selectively bind to and activate all three alpha receptor subtypes, zolpidem in vitro binds the (alpha1) receptor preferentially. The (alpha1) receptor is found primarily on the Lamina IV of the sensorimotor cortical regions, substantia nigra (pars reticulata), cerebellum molecular layer, olfactory bulb, ventral thalamic complex, pons, inferior colliculus, and globus pallidus.
Mechanism of actionZolpidem modulates the alpha-subunit, known as the benzodiazepine receptor, within the GABAA receptor chloride channel macromolecular complex. Unlike the benzodiazepines, which non-selectively interact with all three alpha-receptor subtypes, Zolpidem preferentially binds to the alpha-1 receptor.
Related Articles
AbsorptionZolpidem is rapidly absorbed from the GI tract.
Volume of distributionNot Available
Protein binding92.5 ± 0.1% (independent of concentration between 40 and 790 ng/mL)
Metabolism

Zolpidem is converted to inactive metabolites in the liver.

SubstrateEnzymesProduct
Zolpidem
Methoxyzolpidem derivative (M3)Details
Zolpidem
Methoxyzolpidem derivative (M4)Details
Zolpidem
Not Available
Methoxyzolpidem derivative (M11)Details
Methoxyzolpidem derivative (M4)
Not Available
Zolpidem carboxylic acid derivative (M2)Details
Methoxyzolpidem derivative (M3)
Not Available
Zolpidem carboxylic acid derivative (M1)Details
Route of eliminationZolpidem tartrate tablets are converted to inactive metabolites that are eliminated primarily by renal excretion.
Half life2.6 hours
ClearanceNot Available
ToxicityOral (male rat) LD50 = 695 mg/kg. Symptoms of overdose include impairment of consciousness ranging from somnolence to light coma.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9392
Caco-2 permeable+0.6638
P-glycoprotein substrateSubstrate0.5
P-glycoprotein inhibitor IInhibitor0.8564
P-glycoprotein inhibitor IINon-inhibitor0.7574
Renal organic cation transporterNon-inhibitor0.621
CYP450 2C9 substrateNon-substrate0.7412
CYP450 2D6 substrateSubstrate0.8918
CYP450 3A4 substrateSubstrate0.7407
CYP450 1A2 substrateInhibitor0.624
CYP450 2C9 inhibitorNon-inhibitor0.8331
CYP450 2D6 inhibitorNon-inhibitor0.8754
CYP450 2C19 inhibitorNon-inhibitor0.9119
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.5265
Ames testNon AMES toxic0.5507
CarcinogenicityNon-carcinogens0.8352
BiodegradationNot ready biodegradable0.9928
Rat acute toxicity2.5614 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9831
hERG inhibition (predictor II)Non-inhibitor0.6928
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Novadel pharma inc
  • Sanofi aventis us llc
  • Biovail laboratories international srl
  • Apotex inc
  • Aurobindo pharma ltd
  • Caraco pharmaceutical laboratories ltd
  • Carlsbad technology inc
  • Dr reddys laboratories ltd
  • Genpharm inc
  • Hikma pharmaceuticals
  • Invagen pharmaceuticals inc
  • Lek pharmaceuticals dd
  • Mutual pharmacal co
  • Mylan pharmaceuticals inc
  • Ranbaxy laboratories ltd
  • Roxane laboratories inc
  • Synthon pharmaceuticals ltd
  • Teva pharmaceuticals usa inc
  • Torrent pharmaceuticals ltd
  • Vintage pharmaceuticals llc
  • Watson laboratories inc
  • Wockhardt ltd
  • World gen llc
  • Meda pharmaceuticals
  • Pfizer inc
Packagers
Dosage forms
FormRouteStrength
Tablet, film coatedoral10 mg/1
Tablet, film coatedoral5 mg/1
Tabletoral6.25 mg/1
Tablet, coatedoral12.5 mg/1
Tablet, coatedoral6.25 mg/1
Tablet (orally disintegrating)sublingual10 mg
Tablet (orally disintegrating)sublingual5 mg
Tabletoral10 mg/1
Tabletoral5 mg/1
Kit
Tabletsublingual1.75 mg/1
Tabletsublingual3.5 mg/1
Tabletoral10 mg
Tabletoral5 mg
Kitoral
Tablet, coatedoral10 mg/1
Tablet, coatedoral5 mg/1
Tablet, extended releaseoral12.5 mg/1
Tablet, extended releaseoral6.25 mg/1
Tablet, film coated, extended releaseoral12.5 mg/1
Tablet, film coated, extended releaseoral6.25 mg/1
Spray, meteredoral5 mg/1
Prices
Unit descriptionCostUnit
Ambien cr 12.5 mg tablet6.19USD tablet
Ambien cr 6.25 mg tablet6.19USD tablet
Ambien 10 mg tablet6.11USD tablet
Ambien 5 mg tablet6.04USD tablet
Ambien CR 12.5 mg Controlled Release Tabs6.0USD tab
Ambien CR 6.25 mg Controlled Release Tabs6.0USD tab
Edluar 10 mg sl tablet5.0USD tablet
Edluar 5 mg sl tablet5.0USD tablet
Zolpidem tartrate 10 mg tablet2.73USD tablet
Zolpidem tartrate 5 mg tablet2.73USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6514531 Yes2000-06-012020-06-01Us
US6761910 No1999-09-242019-09-24Us
US7632517 No1997-10-012017-10-01Us
US7658945 No2007-04-152027-04-15Us
US7682628 No2005-02-162025-02-16Us
US8242131 No2009-08-202029-08-20Us
US8252809 No2005-02-162025-02-16Us
US8512747 No1999-09-242019-09-24Us
US9265720 No2010-05-132030-05-13Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point196 °CPhysProp
water solubility23 mg/mLNot Available
logP1.2Not Available
pKa6.2MERCK INDEX (1996)
Predicted Properties
PropertyValueSource
Water Solubility0.0313 mg/mLALOGPS
logP3.15ALOGPS
logP3.02ChemAxon
logS-4ALOGPS
pKa (Strongest Basic)5.65ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area37.61 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity93.58 m3·mol-1ChemAxon
Polarizability35.06 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-000i-1090000000-5429f5620534a2340098View in MoNA
References
Synthesis Reference

Markus Sauter, “Process for preparing zolpidem.” U.S. Patent US20020183522, issued December 05, 2002.

US20020183522
General References
  1. Lemmer B: The sleep-wake cycle and sleeping pills. Physiol Behav. 2007 Feb 28;90(2-3):285-93. Epub 2006 Oct 16. [PubMed:17049955 ]
  2. Depoortere H, Zivkovic B, Lloyd KG, Sanger DJ, Perrault G, Langer SZ, Bartholini G: Zolpidem, a novel nonbenzodiazepine hypnotic. I. Neuropharmacological and behavioral effects. J Pharmacol Exp Ther. 1986 May;237(2):649-58. [PubMed:2871178 ]
  3. Clauss RP, Guldenpfennig WM, Nel HW, Sathekge MM, Venkannagari RR: Extraordinary arousal from semi-comatose state on zolpidem. A case report. S Afr Med J. 2000 Jan;90(1):68-72. [PubMed:10721397 ]
  4. Schlich D, L'Heritier C, Coquelin JP, Attali P, Kryrein HJ: Long-term treatment of insomnia with zolpidem: a multicentre general practitioner study of 107 patients. J Int Med Res. 1991 May-Jun;19(3):271-9. [PubMed:1670039 ]
  5. Maarek L, Cramer P, Attali P, Coquelin JP, Morselli PL: The safety and efficacy of zolpidem in insomniac patients: a long-term open study in general practice. J Int Med Res. 1992 Apr;20(2):162-70. [PubMed:1521672 ]
External Links
ATC CodesN05CF02
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelDownload (323 KB)
MSDSDownload (170 KB)
Interactions
Drug Interactions
Drug
2-HYDROXY-1,4-NAPHTHOQUINONEThe serum concentration of Zolpidem can be increased when it is combined with 2-HYDROXY-1,4-NAPHTHOQUINONE.
2-mercaptobenzothiazoleThe serum concentration of Zolpidem can be increased when it is combined with 2-mercaptobenzothiazole.
7-NitroindazoleThe risk or severity of adverse effects can be increased when Zolpidem is combined with 7-Nitroindazole.
AbirateroneThe serum concentration of Zolpidem can be increased when it is combined with Abiraterone.
AcepromazineThe risk or severity of adverse effects can be increased when Zolpidem is combined with Acepromazine.
AceprometazineThe risk or severity of adverse effects can be increased when Zolpidem is combined with Aceprometazine.
adipiplonThe risk or severity of adverse effects can be increased when Zolpidem is combined with adipiplon.
AgomelatineThe risk or severity of adverse effects can be increased when Zolpidem is combined with Agomelatine.
AlfaxaloneThe risk or severity of adverse effects can be increased when Zolpidem is combined with Alfaxalone.
AlfentanilThe risk or severity of adverse effects can be increased when Zolpidem is combined with Alfentanil.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Zolpidem is combined with Alphacetylmethadol.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Zolpidem.
AmiodaroneThe metabolism of Zolpidem can be decreased when combined with Amiodarone.
AmisulprideThe risk or severity of adverse effects can be increased when Zolpidem is combined with Amisulpride.
AmitriptylineThe risk or severity of adverse effects can be increased when Zolpidem is combined with Amitriptyline.
AmobarbitalThe risk or severity of adverse effects can be increased when Zolpidem is combined with Amobarbital.
AmorolfineThe serum concentration of Zolpidem can be increased when it is combined with Amorolfine.
AmoxapineThe risk or severity of adverse effects can be increased when Zolpidem is combined with Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Zolpidem is combined with Amperozide.
Amphotericin BThe serum concentration of Zolpidem can be increased when it is combined with Amphotericin B.
AN2690The serum concentration of Zolpidem can be increased when it is combined with AN2690.
AnidulafunginThe serum concentration of Zolpidem can be increased when it is combined with Anidulafungin.
AprepitantThe serum concentration of Zolpidem can be increased when it is combined with Aprepitant.
AripiprazoleThe risk or severity of adverse effects can be increased when Zolpidem is combined with Aripiprazole.
ArmodafinilThe metabolism of Zolpidem can be decreased when combined with Armodafinil.
ArtemetherThe metabolism of Zolpidem can be decreased when combined with Artemether.
ArticaineThe risk or severity of adverse effects can be increased when Zolpidem is combined with Articaine.
AsenapineThe risk or severity of adverse effects can be increased when Zolpidem is combined with Asenapine.
AtazanavirThe metabolism of Zolpidem can be decreased when combined with Atazanavir.
AtomoxetineThe metabolism of Zolpidem can be decreased when combined with Atomoxetine.
AzaperoneThe risk or severity of adverse effects can be increased when Zolpidem is combined with Azaperone.
AzelastineZolpidem may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Zolpidem.
AzithromycinThe metabolism of Zolpidem can be decreased when combined with Azithromycin.
BaclofenThe risk or severity of adverse effects can be increased when Zolpidem is combined with Baclofen.
Bafilomycin A1The serum concentration of Zolpidem can be increased when it is combined with Bafilomycin A1.
BarbitalThe risk or severity of adverse effects can be increased when Zolpidem is combined with Barbital.
BenzocaineThe risk or severity of adverse effects can be increased when Zolpidem is combined with Benzocaine.
Benzoic AcidThe serum concentration of Zolpidem can be increased when it is combined with Benzoic Acid.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Zolpidem is combined with Benzyl alcohol.
BetaxololThe metabolism of Zolpidem can be decreased when combined with Betaxolol.
BexaroteneThe serum concentration of Zolpidem can be decreased when it is combined with Bexarotene.
BifonazoleThe serum concentration of Zolpidem can be increased when it is combined with Bifonazole.
BoceprevirThe metabolism of Zolpidem can be decreased when combined with Boceprevir.
BortezomibThe metabolism of Zolpidem can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Zolpidem can be decreased when it is combined with Bosentan.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Zolpidem is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
BrimonidineThe risk or severity of adverse effects can be increased when Zolpidem is combined with Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Zolpidem is combined with Bromazepam.
BrompheniramineThe risk or severity of adverse effects can be increased when Zolpidem is combined with Brompheniramine.
BrotizolamThe risk or severity of adverse effects can be increased when Zolpidem is combined with Brotizolam.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Zolpidem.
BuprenorphineThe risk or severity of adverse effects can be increased when Zolpidem is combined with Buprenorphine.
BupropionThe metabolism of Zolpidem can be decreased when combined with Bupropion.
BuspironeThe risk or severity of adverse effects can be increased when Zolpidem is combined with Buspirone.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Zolpidem.
ButacaineThe risk or severity of adverse effects can be increased when Zolpidem is combined with Butacaine.
ButalbitalThe risk or severity of adverse effects can be increased when Zolpidem is combined with Butalbital.
ButambenThe risk or severity of adverse effects can be increased when Zolpidem is combined with Butamben.
ButenafineThe serum concentration of Zolpidem can be increased when it is combined with Butenafine.
ButethalThe risk or severity of adverse effects can be increased when Zolpidem is combined with Butethal.
ButoconazoleThe serum concentration of Zolpidem can be increased when it is combined with Butoconazole.
ButorphanolThe risk or severity of adverse effects can be increased when Zolpidem is combined with Butorphanol.
CaffeineThe metabolism of Zolpidem can be decreased when combined with Caffeine.
CandicidinThe serum concentration of Zolpidem can be increased when it is combined with Candicidin.
CapecitabineThe metabolism of Zolpidem can be decreased when combined with Capecitabine.
CarbamazepineZolpidem may increase the central nervous system depressant (CNS depressant) activities of Carbamazepine.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Zolpidem.
CarbinoxamineThe risk or severity of adverse effects can be increased when Zolpidem is combined with Carbinoxamine.
CarfentanilThe risk or severity of adverse effects can be increased when Zolpidem is combined with Carfentanil.
CarisoprodolThe risk or severity of adverse effects can be increased when Zolpidem is combined with Carisoprodol.
CaspofunginThe serum concentration of Zolpidem can be increased when it is combined with Caspofungin.
CelecoxibThe metabolism of Zolpidem can be decreased when combined with Celecoxib.
CeritinibThe serum concentration of Zolpidem can be increased when it is combined with Ceritinib.
CeruleninThe serum concentration of Zolpidem can be increased when it is combined with Cerulenin.
CetirizineThe risk or severity of adverse effects can be increased when Zolpidem is combined with Cetirizine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Zolpidem is combined with Chloral hydrate.
ChloramphenicolThe metabolism of Zolpidem can be decreased when combined with Chloramphenicol.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Zolpidem is combined with Chlordiazepoxide.
ChlormezanoneThe risk or severity of adverse effects can be increased when Zolpidem is combined with Chlormezanone.
ChloroprocaineThe risk or severity of adverse effects can be increased when Zolpidem is combined with Chloroprocaine.
ChloroquineThe metabolism of Zolpidem can be decreased when combined with Chloroquine.
ChloroxineThe serum concentration of Zolpidem can be increased when it is combined with Chloroxine.
ChlorphenamineThe risk or severity of adverse effects can be increased when Zolpidem is combined with Chlorphenamine.
ChlorpromazineThe metabolism of Zolpidem can be decreased when combined with Chlorpromazine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Zolpidem is combined with Chlorpromazine.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Zolpidem is combined with Chlorprothixene.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Zolpidem is combined with Chlorzoxazone.
CholecalciferolThe metabolism of Zolpidem can be decreased when combined with Cholecalciferol.
CiclopiroxThe serum concentration of Zolpidem can be increased when it is combined with Ciclopirox.
CimetidineThe metabolism of Zolpidem can be decreased when combined with Cimetidine.
CinacalcetThe metabolism of Zolpidem can be decreased when combined with Cinacalcet.
CinchocaineThe risk or severity of adverse effects can be increased when Zolpidem is combined with Cinchocaine.
CitalopramThe risk or severity of adverse effects can be increased when Zolpidem is combined with Citalopram.
CitalopramThe metabolism of Zolpidem can be decreased when combined with Citalopram.
ClarithromycinThe metabolism of Zolpidem can be decreased when combined with Clarithromycin.
ClemastineThe metabolism of Zolpidem can be decreased when combined with Clemastine.
ClemastineThe risk or severity of adverse effects can be increased when Zolpidem is combined with Clemastine.
ClidiniumThe risk or severity of adverse effects can be increased when Zolpidem is combined with Clidinium.
ClobazamThe metabolism of Zolpidem can be decreased when combined with Clobazam.
ClobazamThe risk or severity of adverse effects can be increased when Zolpidem is combined with Clobazam.
clomethiazoleThe risk or severity of adverse effects can be increased when Zolpidem is combined with clomethiazole.
ClomipramineThe risk or severity of adverse effects can be increased when Zolpidem is combined with Clomipramine.
ClomipramineThe metabolism of Zolpidem can be decreased when combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Zolpidem is combined with Clonazepam.
ClonidineThe risk or severity of adverse effects can be increased when Zolpidem is combined with Clonidine.
ClorazepateThe risk or severity of adverse effects can be increased when Zolpidem is combined with Clorazepate.
ClotrimazoleThe metabolism of Zolpidem can be decreased when combined with Clotrimazole.
ClozapineThe metabolism of Zolpidem can be decreased when combined with Clozapine.
ClozapineThe risk or severity of adverse effects can be increased when Zolpidem is combined with Clozapine.
CobicistatThe serum concentration of Zolpidem can be increased when it is combined with Cobicistat.
CocaineThe risk or severity of adverse effects can be increased when Zolpidem is combined with Cocaine.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Zolpidem.
ConivaptanThe serum concentration of Zolpidem can be increased when it is combined with Conivaptan.
CrizotinibThe metabolism of Zolpidem can be decreased when combined with Crizotinib.
CyclizineThe risk or severity of adverse effects can be increased when Zolpidem is combined with Cyclizine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Zolpidem is combined with Cyclobenzaprine.
CyclosporineThe metabolism of Zolpidem can be decreased when combined with Cyclosporine.
CyproheptadineThe risk or severity of adverse effects can be increased when Zolpidem is combined with Cyproheptadine.
Cyproterone acetateThe serum concentration of Zolpidem can be decreased when it is combined with Cyproterone acetate.
DabrafenibThe serum concentration of Zolpidem can be decreased when it is combined with Dabrafenib.
DantroleneThe risk or severity of adverse effects can be increased when Zolpidem is combined with Dantrolene.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Zolpidem.
DapoxetineThe risk or severity of adverse effects can be increased when Zolpidem is combined with Dapoxetine.
DarifenacinThe metabolism of Zolpidem can be decreased when combined with Darifenacin.
DarunavirThe serum concentration of Zolpidem can be increased when it is combined with Darunavir.
DasatinibThe serum concentration of Zolpidem can be increased when it is combined with Dasatinib.
Decanoic AcidThe serum concentration of Zolpidem can be increased when it is combined with Decanoic Acid.
DeferasiroxThe serum concentration of Zolpidem can be decreased when it is combined with Deferasirox.
DelavirdineThe metabolism of Zolpidem can be decreased when combined with Delavirdine.
deramciclaneThe risk or severity of adverse effects can be increased when Zolpidem is combined with deramciclane.
DesfluraneThe risk or severity of adverse effects can be increased when Zolpidem is combined with Desflurane.
DesipramineThe metabolism of Zolpidem can be decreased when combined with Desipramine.
DesipramineThe risk or severity of adverse effects can be increased when Zolpidem is combined with Desipramine.
DesloratadineThe risk or severity of adverse effects can be increased when Zolpidem is combined with Desloratadine.
DetomidineThe risk or severity of adverse effects can be increased when Zolpidem is combined with Detomidine.
DexamethasoneThe serum concentration of Zolpidem can be decreased when it is combined with Dexamethasone.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Zolpidem is combined with Dexbrompheniramine.
DexmedetomidineThe risk or severity of adverse effects can be increased when Zolpidem is combined with Dexmedetomidine.
DextromoramideThe risk or severity of adverse effects can be increased when Zolpidem is combined with Dextromoramide.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Zolpidem is combined with Dextropropoxyphene.
DezocineThe risk or severity of adverse effects can be increased when Zolpidem is combined with Dezocine.
DiazepamThe risk or severity of adverse effects can be increased when Zolpidem is combined with Diazepam.
DifenoxinThe risk or severity of adverse effects can be increased when Zolpidem is combined with Difenoxin.
DihydrocodeineThe risk or severity of adverse effects can be increased when Zolpidem is combined with Dihydrocodeine.
DihydroergotamineThe metabolism of Zolpidem can be decreased when combined with Dihydroergotamine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Zolpidem is combined with Dihydroetorphine.
DihydromorphineThe risk or severity of adverse effects can be increased when Zolpidem is combined with Dihydromorphine.
DiltiazemThe metabolism of Zolpidem can be decreased when combined with Diltiazem.
DimenhydrinateThe risk or severity of adverse effects can be increased when Zolpidem is combined with Dimenhydrinate.
DiphenhydramineThe metabolism of Zolpidem can be decreased when combined with Diphenhydramine.
DiphenhydramineThe risk or severity of adverse effects can be increased when Zolpidem is combined with Diphenhydramine.
DiphenoxylateThe risk or severity of adverse effects can be increased when Zolpidem is combined with Diphenoxylate.
DoramectinThe risk or severity of adverse effects can be increased when Zolpidem is combined with Doramectin.
DoxepinThe risk or severity of adverse effects can be increased when Zolpidem is combined with Doxepin.
DoxycyclineThe metabolism of Zolpidem can be decreased when combined with Doxycycline.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
DoxylamineThe risk or severity of adverse effects can be increased when Zolpidem is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when Zolpidem is combined with DPDPE.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
DronedaroneThe metabolism of Zolpidem can be decreased when combined with Dronedarone.
DroperidolThe risk or severity of adverse effects can be increased when Zolpidem is combined with Droperidol.
DrotebanolThe risk or severity of adverse effects can be increased when Zolpidem is combined with Drotebanol.
DuloxetineThe metabolism of Zolpidem can be decreased when combined with Duloxetine.
DyclonineThe risk or severity of adverse effects can be increased when Zolpidem is combined with Dyclonine.
EcgonineThe risk or severity of adverse effects can be increased when Zolpidem is combined with Ecgonine.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Zolpidem is combined with ECGONINE METHYL ESTER.
EconazoleThe serum concentration of Zolpidem can be increased when it is combined with Econazole.
EfavirenzThe serum concentration of Zolpidem can be decreased when it is combined with Efavirenz.
EfavirenzThe risk or severity of adverse effects can be increased when Zolpidem is combined with Efavirenz.
EfinaconazoleThe serum concentration of Zolpidem can be increased when it is combined with Efinaconazole.
EliglustatThe metabolism of Zolpidem can be decreased when combined with Eliglustat.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Zolpidem.
EntacaponeThe risk or severity of adverse effects can be increased when Zolpidem is combined with Entacapone.
EnzalutamideThe serum concentration of Zolpidem can be decreased when it is combined with Enzalutamide.
ErythromycinThe metabolism of Zolpidem can be decreased when combined with Erythromycin.
EscitalopramThe risk or severity of adverse effects can be increased when Zolpidem is combined with Escitalopram.
Eslicarbazepine acetateThe serum concentration of Zolpidem can be decreased when it is combined with Eslicarbazepine acetate.
EsomeprazoleThe metabolism of Zolpidem can be decreased when combined with Esomeprazole.
EstazolamThe risk or severity of adverse effects can be increased when Zolpidem is combined with Estazolam.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Zolpidem.
EthanolZolpidem may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Zolpidem.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Zolpidem.
EthosuximideThe risk or severity of adverse effects can be increased when Zolpidem is combined with Ethosuximide.
EthotoinThe risk or severity of adverse effects can be increased when Zolpidem is combined with Ethotoin.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Zolpidem is combined with Ethyl carbamate.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Zolpidem is combined with Ethyl loflazepate.
EthylmorphineThe risk or severity of adverse effects can be increased when Zolpidem is combined with Ethylmorphine.
EtidocaineThe risk or severity of adverse effects can be increased when Zolpidem is combined with Etidocaine.
EtifoxineThe risk or severity of adverse effects can be increased when Zolpidem is combined with Etifoxine.
EtizolamThe risk or severity of adverse effects can be increased when Zolpidem is combined with Etizolam.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Zolpidem.
EtoperidoneThe risk or severity of adverse effects can be increased when Zolpidem is combined with Etoperidone.
EtorphineThe risk or severity of adverse effects can be increased when Zolpidem is combined with Etorphine.
EtravirineThe serum concentration of Zolpidem can be decreased when it is combined with Etravirine.
EzogabineThe risk or severity of adverse effects can be increased when Zolpidem is combined with Ezogabine.
FelbamateThe risk or severity of adverse effects can be increased when Zolpidem is combined with Felbamate.
FencamfamineThe risk or severity of adverse effects can be increased when Zolpidem is combined with Fencamfamine.
FenfluramineThe risk or severity of adverse effects can be increased when Zolpidem is combined with Fenfluramine.
FentanylThe risk or severity of adverse effects can be increased when Zolpidem is combined with Fentanyl.
FexofenadineThe risk or severity of adverse effects can be increased when Zolpidem is combined with Fexofenadine.
FlibanserinThe risk or severity of adverse effects can be increased when Zolpidem is combined with Flibanserin.
FloxuridineThe metabolism of Zolpidem can be decreased when combined with Floxuridine.
FluconazoleThe metabolism of Zolpidem can be decreased when combined with Fluconazole.
FlucytosineThe serum concentration of Zolpidem can be increased when it is combined with Flucytosine.
FludiazepamThe risk or severity of adverse effects can be increased when Zolpidem is combined with Fludiazepam.
FlumazenilFlumazenil may decrease the sedative activities of Zolpidem.
FlunarizineThe risk or severity of adverse effects can be increased when Zolpidem is combined with Flunarizine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Zolpidem is combined with Flunitrazepam.
FluorouracilThe metabolism of Zolpidem can be decreased when combined with Fluorouracil.
FluoxetineThe risk or severity of adverse effects can be increased when Zolpidem is combined with Fluoxetine.
FluoxetineThe metabolism of Zolpidem can be decreased when combined with Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Zolpidem is combined with Flupentixol.
FluphenazineThe risk or severity of adverse effects can be increased when Zolpidem is combined with Fluphenazine.
FlurazepamThe risk or severity of adverse effects can be increased when Zolpidem is combined with Flurazepam.
FluspirileneThe risk or severity of adverse effects can be increased when Zolpidem is combined with Fluspirilene.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Zolpidem is combined with Fluticasone Propionate.
FluvastatinThe metabolism of Zolpidem can be decreased when combined with Fluvastatin.
FluvoxamineFluvoxamine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
FluvoxamineThe risk or severity of adverse effects can be increased when Zolpidem is combined with Fluvoxamine.
FosamprenavirThe metabolism of Zolpidem can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Zolpidem can be increased when it is combined with Fosaprepitant.
FosphenytoinThe risk or severity of adverse effects can be increased when Zolpidem is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Zolpidem is combined with Fospropofol.
Fusidic AcidThe serum concentration of Zolpidem can be increased when it is combined with Fusidic Acid.
GabapentinThe risk or severity of adverse effects can be increased when Zolpidem is combined with Gabapentin.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Zolpidem is combined with gabapentin enacarbil.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Zolpidem is combined with Gamma Hydroxybutyric Acid.
GemfibrozilThe metabolism of Zolpidem can be decreased when combined with Gemfibrozil.
GlutethimideThe risk or severity of adverse effects can be increased when Zolpidem is combined with Glutethimide.
GlyphosateThe serum concentration of Zolpidem can be increased when it is combined with Glyphosate.
GriseofulvinThe serum concentration of Zolpidem can be increased when it is combined with Griseofulvin.
GuanfacineThe risk or severity of adverse effects can be increased when Zolpidem is combined with Guanfacine.
HalazepamThe risk or severity of adverse effects can be increased when Zolpidem is combined with Halazepam.
HaloperidolThe metabolism of Zolpidem can be decreased when combined with Haloperidol.
HaloperidolThe risk or severity of adverse effects can be increased when Zolpidem is combined with Haloperidol.
HaloproginThe serum concentration of Zolpidem can be increased when it is combined with Haloprogin.
HalothaneThe risk or severity of adverse effects can be increased when Zolpidem is combined with Halothane.
HeroinThe risk or severity of adverse effects can be increased when Zolpidem is combined with Heroin.
HexetidineThe serum concentration of Zolpidem can be increased when it is combined with Hexetidine.
HexobarbitalThe risk or severity of adverse effects can be increased when Zolpidem is combined with Hexobarbital.
HydrocodoneThe risk or severity of adverse effects can be increased when Zolpidem is combined with Hydrocodone.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Zolpidem.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
HydroxyzineThe risk or severity of adverse effects can be increased when Zolpidem is combined with Hydroxyzine.
IdelalisibThe serum concentration of Zolpidem can be increased when it is combined with Idelalisib.
IloperidoneThe risk or severity of adverse effects can be increased when Zolpidem is combined with Iloperidone.
ImatinibThe metabolism of Zolpidem can be decreased when combined with Imatinib.
ImipramineThe metabolism of Zolpidem can be decreased when combined with Imipramine.
ImipramineThe risk or severity of adverse effects can be increased when Zolpidem is combined with Imipramine.
IndalpineThe risk or severity of adverse effects can be increased when Zolpidem is combined with Indalpine.
IndinavirThe metabolism of Zolpidem can be decreased when combined with Indinavir.
IrbesartanThe metabolism of Zolpidem can be decreased when combined with Irbesartan.
IsavuconazoniumThe metabolism of Zolpidem can be decreased when combined with Isavuconazonium.
IsoconazoleThe serum concentration of Zolpidem can be increased when it is combined with Isoconazole.
IsofluraneThe risk or severity of adverse effects can be increased when Zolpidem is combined with Isoflurane.
IsoniazidThe metabolism of Zolpidem can be decreased when combined with Isoniazid.
IsradipineThe metabolism of Zolpidem can be decreased when combined with Isradipine.
ItraconazoleThe serum concentration of Zolpidem can be increased when it is combined with Itraconazole.
IvacaftorThe serum concentration of Zolpidem can be increased when it is combined with Ivacaftor.
KetamineThe risk or severity of adverse effects can be increased when Zolpidem is combined with Ketamine.
KetazolamThe risk or severity of adverse effects can be increased when Zolpidem is combined with Ketazolam.
KetobemidoneThe risk or severity of adverse effects can be increased when Zolpidem is combined with Ketobemidone.
KetoconazoleThe metabolism of Zolpidem can be decreased when combined with Ketoconazole.
LamotrigineThe risk or severity of adverse effects can be increased when Zolpidem is combined with Lamotrigine.
LeflunomideThe metabolism of Zolpidem can be decreased when combined with Leflunomide.
LevetiracetamThe risk or severity of adverse effects can be increased when Zolpidem is combined with Levetiracetam.
LevobupivacaineThe risk or severity of adverse effects can be increased when Zolpidem is combined with Levobupivacaine.
LevocabastineThe risk or severity of adverse effects can be increased when Zolpidem is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Zolpidem is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Zolpidem is combined with Levodopa.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Zolpidem is combined with Levomethadyl Acetate.
LevomilnacipranThe risk or severity of adverse effects can be increased when Zolpidem is combined with Levomilnacipran.
LevorphanolThe risk or severity of adverse effects can be increased when Zolpidem is combined with Levorphanol.
LidocaineThe metabolism of Zolpidem can be decreased when combined with Lidocaine.
LidocaineThe risk or severity of adverse effects can be increased when Zolpidem is combined with Lidocaine.
LithiumThe risk or severity of adverse effects can be increased when Zolpidem is combined with Lithium.
LofentanilThe risk or severity of adverse effects can be increased when Zolpidem is combined with Lofentanil.
LopinavirThe metabolism of Zolpidem can be decreased when combined with Lopinavir.
LoratadineThe risk or severity of adverse effects can be increased when Zolpidem is combined with Loratadine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Zolpidem.
LorcaserinThe metabolism of Zolpidem can be decreased when combined with Lorcaserin.
LosartanThe metabolism of Zolpidem can be decreased when combined with Losartan.
LovastatinThe metabolism of Zolpidem can be decreased when combined with Lovastatin.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Zolpidem.
Lu AA21004The risk or severity of adverse effects can be increased when Zolpidem is combined with Lu AA21004.
LuliconazoleThe serum concentration of Zolpidem can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Zolpidem can be decreased when it is combined with Lumacaftor.
LumefantrineThe metabolism of Zolpidem can be decreased when combined with Lumefantrine.
LurasidoneThe risk or severity of adverse effects can be increased when Zolpidem is combined with Lurasidone.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Zolpidem is combined with Magnesium Sulfate.
MaprotilineThe risk or severity of adverse effects can be increased when Zolpidem is combined with Maprotiline.
MeclizineThe risk or severity of adverse effects can be increased when Zolpidem is combined with Meclizine.
MedetomidineThe risk or severity of adverse effects can be increased when Zolpidem is combined with Medetomidine.
MelatoninThe risk or severity of adverse effects can be increased when Zolpidem is combined with Melatonin.
MelperoneThe risk or severity of adverse effects can be increased when Zolpidem is combined with Melperone.
MepivacaineThe risk or severity of adverse effects can be increased when Zolpidem is combined with Mepivacaine.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Zolpidem.
MesoridazineThe risk or severity of adverse effects can be increased when Zolpidem is combined with Mesoridazine.
MetaxaloneThe risk or severity of adverse effects can be increased when Zolpidem is combined with Metaxalone.
MethadoneThe metabolism of Zolpidem can be decreased when combined with Methadone.
MethadoneThe risk or severity of adverse effects can be increased when Zolpidem is combined with Methadone.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Zolpidem is combined with Methadyl Acetate.
MethapyrileneThe risk or severity of adverse effects can be increased when Zolpidem is combined with Methapyrilene.
MethaqualoneThe risk or severity of adverse effects can be increased when Zolpidem is combined with Methaqualone.
MethocarbamolThe risk or severity of adverse effects can be increased when Zolpidem is combined with Methocarbamol.
MethohexitalThe risk or severity of adverse effects can be increased when Zolpidem is combined with Methohexital.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Zolpidem is combined with Methotrimeprazine.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Zolpidem is combined with Methoxyflurane.
MethsuximideThe risk or severity of adverse effects can be increased when Zolpidem is combined with Methsuximide.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Zolpidem is combined with Methylphenobarbital.
MetoprololThe metabolism of Zolpidem can be decreased when combined with Metoprolol.
MetyrosineZolpidem may increase the sedative activities of Metyrosine.
MevastatinThe serum concentration of Zolpidem can be increased when it is combined with Mevastatin.
MexiletineThe metabolism of Zolpidem can be decreased when combined with Mexiletine.
MicafunginThe serum concentration of Zolpidem can be increased when it is combined with Micafungin.
MiconazoleThe serum concentration of Zolpidem can be increased when it is combined with Miconazole.
MidazolamThe risk or severity of adverse effects can be increased when Zolpidem is combined with Midazolam.
MifepristoneThe metabolism of Zolpidem can be decreased when combined with Mifepristone.
MilnacipranThe risk or severity of adverse effects can be increased when Zolpidem is combined with Milnacipran.
MiltefosineThe serum concentration of Zolpidem can be increased when it is combined with Miltefosine.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
MirabegronThe metabolism of Zolpidem can be decreased when combined with Mirabegron.
MirtazapineZolpidem may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Zolpidem.
MitotaneThe serum concentration of Zolpidem can be decreased when it is combined with Mitotane.
MoclobemideThe metabolism of Zolpidem can be decreased when combined with Moclobemide.
ModafinilThe serum concentration of Zolpidem can be decreased when it is combined with Modafinil.
MolindoneThe risk or severity of adverse effects can be increased when Zolpidem is combined with Molindone.
MonensinThe serum concentration of Zolpidem can be increased when it is combined with Monensin.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Zolpidem.
MyxothiazolThe serum concentration of Zolpidem can be increased when it is combined with Myxothiazol.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
NabiloneThe risk or severity of adverse effects can be increased when Zolpidem is combined with Nabilone.
NafcillinThe serum concentration of Zolpidem can be decreased when it is combined with Nafcillin.
NaftifineThe serum concentration of Zolpidem can be increased when it is combined with Naftifine.
NalbuphineThe risk or severity of adverse effects can be increased when Zolpidem is combined with Nalbuphine.
NatamycinThe serum concentration of Zolpidem can be increased when it is combined with Natamycin.
NefazodoneThe metabolism of Zolpidem can be decreased when combined with Nefazodone.
NelfinavirThe metabolism of Zolpidem can be decreased when combined with Nelfinavir.
NetupitantThe serum concentration of Zolpidem can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Zolpidem can be decreased when combined with Nevirapine.
NicardipineThe metabolism of Zolpidem can be decreased when combined with Nicardipine.
NilotinibThe metabolism of Zolpidem can be decreased when combined with Nilotinib.
NitrazepamThe risk or severity of adverse effects can be increased when Zolpidem is combined with Nitrazepam.
Nitrous oxideThe risk or severity of adverse effects can be increased when Zolpidem is combined with Nitrous oxide.
NitroxolineThe serum concentration of Zolpidem can be increased when it is combined with Nitroxoline.
NormethadoneThe risk or severity of adverse effects can be increased when Zolpidem is combined with Normethadone.
NortriptylineThe risk or severity of adverse effects can be increased when Zolpidem is combined with Nortriptyline.
NystatinThe serum concentration of Zolpidem can be increased when it is combined with Nystatin.
OlanzapineThe risk or severity of adverse effects can be increased when Zolpidem is combined with Olanzapine.
OlaparibThe metabolism of Zolpidem can be decreased when combined with Olaparib.
OlopatadineThe risk or severity of adverse effects can be increased when Zolpidem is combined with Olopatadine.
OmeprazoleThe metabolism of Zolpidem can be decreased when combined with Omeprazole.
OndansetronThe risk or severity of adverse effects can be increased when Zolpidem is combined with Ondansetron.
OpiumThe risk or severity of adverse effects can be increased when Zolpidem is combined with Opium.
OrphenadrineZolpidem may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Zolpidem.
OsanetantThe risk or severity of adverse effects can be increased when Zolpidem is combined with Osanetant.
OsimertinibThe serum concentration of Zolpidem can be increased when it is combined with Osimertinib.
OxazepamThe risk or severity of adverse effects can be increased when Zolpidem is combined with Oxazepam.
OxiconazoleThe serum concentration of Zolpidem can be increased when it is combined with Oxiconazole.
OxprenololThe risk or severity of adverse effects can be increased when Zolpidem is combined with Oxprenolol.
OxybuprocaineThe risk or severity of adverse effects can be increased when Zolpidem is combined with Oxybuprocaine.
OxycodoneThe risk or severity of adverse effects can be increased when Zolpidem is combined with Oxycodone.
OxymorphoneThe risk or severity of adverse effects can be increased when Zolpidem is combined with Oxymorphone.
pafuramidineThe serum concentration of Zolpidem can be increased when it is combined with pafuramidine.
PalbociclibThe serum concentration of Zolpidem can be increased when it is combined with Palbociclib.
PaliperidoneThe risk or severity of adverse effects can be increased when Zolpidem is combined with Paliperidone.
PanobinostatThe metabolism of Zolpidem can be decreased when combined with Panobinostat.
PantoprazoleThe metabolism of Zolpidem can be decreased when combined with Pantoprazole.
ParaldehydeZolpidem may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Zolpidem.
ParoxetineThe risk or severity of adverse effects can be increased when Zolpidem is combined with Paroxetine.
ParoxetineThe metabolism of Zolpidem can be decreased when combined with Paroxetine.
Peginterferon alfa-2bThe serum concentration of Zolpidem can be decreased when it is combined with Peginterferon alfa-2b.
PentamidineThe serum concentration of Zolpidem can be increased when it is combined with Pentamidine.
PentazocineThe risk or severity of adverse effects can be increased when Zolpidem is combined with Pentazocine.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Zolpidem.
PerampanelThe risk or severity of adverse effects can be increased when Zolpidem is combined with Perampanel.
PerospironeThe risk or severity of adverse effects can be increased when Zolpidem is combined with Perospirone.
PerphenazineThe risk or severity of adverse effects can be increased when Zolpidem is combined with Perphenazine.
PethidineThe risk or severity of adverse effects can be increased when Zolpidem is combined with Pethidine.
PhenobarbitalThe risk or severity of adverse effects can be increased when Zolpidem is combined with Phenobarbital.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Zolpidem is combined with Phenoxyethanol.
PhenytoinThe risk or severity of adverse effects can be increased when Zolpidem is combined with Phenytoin.
PimozideThe risk or severity of adverse effects can be increased when Zolpidem is combined with Pimozide.
PipamperoneThe risk or severity of adverse effects can be increased when Zolpidem is combined with Pipamperone.
PipotiazineThe risk or severity of adverse effects can be increased when Zolpidem is combined with Pipotiazine.
PizotifenThe risk or severity of adverse effects can be increased when Zolpidem is combined with Pizotifen.
PomalidomideThe risk or severity of adverse effects can be increased when Zolpidem is combined with Pomalidomide.
PosaconazoleThe serum concentration of Zolpidem can be increased when it is combined with Posaconazole.
PramipexoleZolpidem may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Zolpidem is combined with Pramocaine.
PrazepamThe risk or severity of adverse effects can be increased when Zolpidem is combined with Prazepam.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Zolpidem.
PrilocaineThe risk or severity of adverse effects can be increased when Zolpidem is combined with Prilocaine.
PrimidoneThe risk or severity of adverse effects can be increased when Zolpidem is combined with Primidone.
ProcaineThe risk or severity of adverse effects can be increased when Zolpidem is combined with Procaine.
ProchlorperazineThe risk or severity of adverse effects can be increased when Zolpidem is combined with Prochlorperazine.
PromazineThe metabolism of Zolpidem can be decreased when combined with Promazine.
PromazineThe risk or severity of adverse effects can be increased when Zolpidem is combined with Promazine.
PromethazineThe risk or severity of adverse effects can be increased when Zolpidem is combined with Promethazine.
ProparacaineThe risk or severity of adverse effects can be increased when Zolpidem is combined with Proparacaine.
PropofolThe risk or severity of adverse effects can be increased when Zolpidem is combined with Propofol.
PropoxycaineThe risk or severity of adverse effects can be increased when Zolpidem is combined with Propoxycaine.
ProtriptylineThe risk or severity of adverse effects can be increased when Zolpidem is combined with Protriptyline.
PSD502The risk or severity of adverse effects can be increased when Zolpidem is combined with PSD502.
PyrimethamineThe metabolism of Zolpidem can be decreased when combined with Pyrimethamine.
QuazepamThe risk or severity of adverse effects can be increased when Zolpidem is combined with Quazepam.
QuetiapineThe risk or severity of adverse effects can be increased when Zolpidem is combined with Quetiapine.
QuinidineThe metabolism of Zolpidem can be decreased when combined with Quinidine.
QuinineThe metabolism of Zolpidem can be decreased when combined with Quinine.
RadicicolThe serum concentration of Zolpidem can be increased when it is combined with Radicicol.
RamelteonThe risk or severity of adverse effects can be increased when Zolpidem is combined with Ramelteon.
RanolazineThe metabolism of Zolpidem can be decreased when combined with Ranolazine.
RemifentanilThe risk or severity of adverse effects can be increased when Zolpidem is combined with Remifentanil.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Zolpidem.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Zolpidem.
RifabutinThe metabolism of Zolpidem can be increased when combined with Rifabutin.
RifampicinThe metabolism of Zolpidem can be increased when combined with Rifampicin.
RifapentineThe metabolism of Zolpidem can be increased when combined with Rifapentine.
RisperidoneThe risk or severity of adverse effects can be increased when Zolpidem is combined with Risperidone.
RitonavirThe metabolism of Zolpidem can be decreased when combined with Ritonavir.
RolapitantThe metabolism of Zolpidem can be decreased when combined with Rolapitant.
RomifidineThe risk or severity of adverse effects can be increased when Zolpidem is combined with Romifidine.
RopiniroleZolpidem may increase the sedative activities of Ropinirole.
RopiniroleThe metabolism of Zolpidem can be decreased when combined with Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Zolpidem.
RotigotineZolpidem may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Zolpidem.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Zolpidem is combined with S-Ethylisothiourea.
Salicylhydroxamic AcidThe serum concentration of Zolpidem can be increased when it is combined with Salicylhydroxamic Acid.
Salicylic acidThe serum concentration of Zolpidem can be increased when it is combined with Salicylic acid.
SaquinavirThe metabolism of Zolpidem can be decreased when combined with Saquinavir.
ScopolamineThe risk or severity of adverse effects can be increased when Zolpidem is combined with Scopolamine.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Zolpidem.
SertaconazoleThe serum concentration of Zolpidem can be increased when it is combined with Sertaconazole.
SertindoleThe risk or severity of adverse effects can be increased when Zolpidem is combined with Sertindole.
SertralineThe risk or severity of adverse effects can be increased when Zolpidem is combined with Sertraline.
SertralineThe metabolism of Zolpidem can be decreased when combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Zolpidem is combined with Sevoflurane.
SildenafilThe metabolism of Zolpidem can be decreased when combined with Sildenafil.
SiltuximabThe serum concentration of Zolpidem can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Zolpidem can be increased when it is combined with Simeprevir.
SinefunginThe serum concentration of Zolpidem can be increased when it is combined with Sinefungin.
SirolimusThe serum concentration of Zolpidem can be increased when it is combined with Sirolimus.
Sodium oxybateZolpidem may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.
Sodium oxybateThe risk or severity of adverse effects can be increased when Sodium oxybate is combined with Zolpidem.
SorafenibThe metabolism of Zolpidem can be decreased when combined with Sorafenib.
St. John's WortThe serum concentration of Zolpidem can be decreased when it is combined with St. John's Wort.
StiripentolThe risk or severity of adverse effects can be increased when Zolpidem is combined with Stiripentol.
SufentanilThe risk or severity of adverse effects can be increased when Zolpidem is combined with Sufentanil.
SulconazoleThe serum concentration of Zolpidem can be increased when it is combined with Sulconazole.
SulfadiazineThe metabolism of Zolpidem can be decreased when combined with Sulfadiazine.
SulfamethoxazoleThe metabolism of Zolpidem can be decreased when combined with Sulfamethoxazole.
SulfisoxazoleThe metabolism of Zolpidem can be decreased when combined with Sulfisoxazole.
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Zolpidem.
SuvorexantThe risk or severity of adverse effects can be increased when Zolpidem is combined with Suvorexant.
TapentadolThe risk or severity of adverse effects can be increased when Zolpidem is combined with Tapentadol.
TasimelteonThe risk or severity of adverse effects can be increased when Zolpidem is combined with Tasimelteon.
TavaboroleThe serum concentration of Zolpidem can be increased when it is combined with Tavaborole.
TelaprevirThe serum concentration of Zolpidem can be decreased when it is combined with Telaprevir.
TelithromycinThe metabolism of Zolpidem can be decreased when combined with Telithromycin.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Zolpidem.
TenofovirThe metabolism of Zolpidem can be decreased when combined with Tenofovir.
TerbinafineThe serum concentration of Zolpidem can be increased when it is combined with Terbinafine.
TerconazoleThe serum concentration of Zolpidem can be increased when it is combined with Terconazole.
TeriflunomideThe serum concentration of Zolpidem can be decreased when it is combined with Teriflunomide.
TetrabenazineThe risk or severity of adverse effects can be increased when Zolpidem is combined with Tetrabenazine.
TetracaineThe risk or severity of adverse effects can be increased when Zolpidem is combined with Tetracaine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Zolpidem is combined with Tetrodotoxin.
ThalidomideZolpidem may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Zolpidem.
TheophyllineThe metabolism of Zolpidem can be decreased when combined with Theophylline.
ThiamylalThe risk or severity of adverse effects can be increased when Zolpidem is combined with Thiamylal.
ThiopentalThe risk or severity of adverse effects can be increased when Zolpidem is combined with Thiopental.
ThioridazineThe risk or severity of adverse effects can be increased when Zolpidem is combined with Thioridazine.
ThiothixeneThe risk or severity of adverse effects can be increased when Zolpidem is combined with Thiothixene.
ThymolThe serum concentration of Zolpidem can be increased when it is combined with Thymol.
TiagabineThe risk or severity of adverse effects can be increased when Zolpidem is combined with Tiagabine.
TicagrelorThe metabolism of Zolpidem can be decreased when combined with Ticagrelor.
TiclopidineThe metabolism of Zolpidem can be decreased when combined with Ticlopidine.
TiletamineThe risk or severity of adverse effects can be increased when Zolpidem is combined with Tiletamine.
TioconazoleThe serum concentration of Zolpidem can be increased when it is combined with Tioconazole.
TipranavirThe metabolism of Zolpidem can be decreased when combined with Tipranavir.
TizanidineThe risk or severity of adverse effects can be increased when Zolpidem is combined with Tizanidine.
TocilizumabThe serum concentration of Zolpidem can be decreased when it is combined with Tocilizumab.
TolbutamideThe metabolism of Zolpidem can be decreased when combined with Tolbutamide.
TolcaponeThe risk or severity of adverse effects can be increased when Zolpidem is combined with Tolcapone.
TolnaftateThe serum concentration of Zolpidem can be increased when it is combined with Tolnaftate.
TopiramateThe risk or severity of adverse effects can be increased when Zolpidem is combined with Topiramate.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Zolpidem.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Zolpidem is combined with Trans-2-Phenylcyclopropylamine.
TranylcypromineThe metabolism of Zolpidem can be decreased when combined with Tranylcypromine.
TranylcypromineThe risk or severity of adverse effects can be increased when Zolpidem is combined with Tranylcypromine.
TrazodoneThe risk or severity of adverse effects can be increased when Zolpidem is combined with Trazodone.
TriazolamThe risk or severity of adverse effects can be increased when Zolpidem is combined with Triazolam.
TrifluoperazineThe risk or severity of adverse effects can be increased when Zolpidem is combined with Trifluoperazine.
TriflupromazineThe risk or severity of adverse effects can be increased when Zolpidem is combined with Triflupromazine.
TrimethoprimThe metabolism of Zolpidem can be decreased when combined with Trimethoprim.
TrimetrexateThe serum concentration of Zolpidem can be increased when it is combined with Trimetrexate.
TrimipramineThe risk or severity of adverse effects can be increased when Zolpidem is combined with Trimipramine.
TriprolidineThe risk or severity of adverse effects can be increased when Zolpidem is combined with Triprolidine.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Zolpidem.
ValsartanThe metabolism of Zolpidem can be decreased when combined with Valsartan.
VemurafenibThe serum concentration of Zolpidem can be increased when it is combined with Vemurafenib.
VenlafaxineThe metabolism of Zolpidem can be decreased when combined with Venlafaxine.
VerapamilThe metabolism of Zolpidem can be decreased when combined with Verapamil.
VigabatrinThe risk or severity of adverse effects can be increased when Zolpidem is combined with Vigabatrin.
VilazodoneThe risk or severity of adverse effects can be increased when Zolpidem is combined with Vilazodone.
VoriconazoleThe metabolism of Zolpidem can be decreased when combined with Voriconazole.
VortioxetineThe risk or severity of adverse effects can be increased when Zolpidem is combined with Vortioxetine.
XylazineThe risk or severity of adverse effects can be increased when Zolpidem is combined with Xylazine.
ZafirlukastThe metabolism of Zolpidem can be decreased when combined with Zafirlukast.
ZaleplonThe risk or severity of adverse effects can be increased when Zolpidem is combined with Zaleplon.
ZiconotideThe risk or severity of adverse effects can be increased when Zolpidem is combined with Ziconotide.
ZimelidineThe risk or severity of adverse effects can be increased when Zolpidem is combined with Zimelidine.
ZiprasidoneThe metabolism of Zolpidem can be decreased when combined with Ziprasidone.
ZiprasidoneThe risk or severity of adverse effects can be increased when Zolpidem is combined with Ziprasidone.
ZolazepamThe risk or severity of adverse effects can be increased when Zolpidem is combined with Zolazepam.
ZonisamideThe risk or severity of adverse effects can be increased when Zolpidem is combined with Zonisamide.
ZopicloneThe risk or severity of adverse effects can be increased when Zolpidem is combined with Zopiclone.
ZotepineThe risk or severity of adverse effects can be increased when Zolpidem is combined with Zotepine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zolpidem is combined with Zuclopenthixol.
Food Interactions
  • Avoid alcohol.
  • Should not be administered with or immediately after a meal.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel (By si...
Gene Name:
GABRA1
Uniprot ID:
P14867
Molecular Weight:
51801.395 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Vlainic J, Pericic D: Effects of acute and repeated zolpidem treatment on pentylenetetrazole-induced seizure threshold and on locomotor activity: comparison with diazepam. Neuropharmacology. 2009 Jun;56(8):1124-30. doi: 10.1016/j.neuropharm.2009.03.010. Epub 2009 Apr 1. [PubMed:19345234 ]
  4. Smith AJ, Alder L, Silk J, Adkins C, Fletcher AE, Scales T, Kerby J, Marshall G, Wafford KA, McKernan RM, Atack JR: Effect of alpha subunit on allosteric modulation of ion channel function in stably expressed human recombinant gamma-aminobutyric acid(A) receptors determined using (36)Cl ion flux. Mol Pharmacol. 2001 May;59(5):1108-18. [PubMed:11306694 ]
  5. Pritchett DB, Seeburg PH: Gamma-aminobutyric acidA receptor alpha 5-subunit creates novel type II benzodiazepine receptor pharmacology. J Neurochem. 1990 May;54(5):1802-4. [PubMed:2157817 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA2
Uniprot ID:
P47869
Molecular Weight:
51325.85 Da
References
  1. Pritchett DB, Seeburg PH: Gamma-aminobutyric acidA receptor alpha 5-subunit creates novel type II benzodiazepine receptor pharmacology. J Neurochem. 1990 May;54(5):1802-4. [PubMed:2157817 ]
  2. Smith AJ, Alder L, Silk J, Adkins C, Fletcher AE, Scales T, Kerby J, Marshall G, Wafford KA, McKernan RM, Atack JR: Effect of alpha subunit on allosteric modulation of ion channel function in stably expressed human recombinant gamma-aminobutyric acid(A) receptors determined using (36)Cl ion flux. Mol Pharmacol. 2001 May;59(5):1108-18. [PubMed:11306694 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA3
Uniprot ID:
P34903
Molecular Weight:
55164.055 Da
References
  1. Pritchett DB, Seeburg PH: Gamma-aminobutyric acidA receptor alpha 5-subunit creates novel type II benzodiazepine receptor pharmacology. J Neurochem. 1990 May;54(5):1802-4. [PubMed:2157817 ]
  2. Smith AJ, Alder L, Silk J, Adkins C, Fletcher AE, Scales T, Kerby J, Marshall G, Wafford KA, McKernan RM, Atack JR: Effect of alpha subunit on allosteric modulation of ion channel function in stably expressed human recombinant gamma-aminobutyric acid(A) receptors determined using (36)Cl ion flux. Mol Pharmacol. 2001 May;59(5):1108-18. [PubMed:11306694 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Wang B, Zhou SF: Synthetic and natural compounds that interact with human cytochrome P450 1A2 and implications in drug development. Curr Med Chem. 2009;16(31):4066-218. [PubMed:19754423 ]
  2. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A7
Uniprot ID:
P24462
Molecular Weight:
57525.03 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gastric epithelial cells, it is a key step in the generation of prostaglandins, such as prostaglandin E2 (PGE2), which plays an important role in cytoprotection. In platelets, it is involved in the gener...
Gene Name:
PTGS1
Uniprot ID:
P23219
Molecular Weight:
68685.82 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 28, 2016 03:41